Bicara Therapeutics (NASDAQ:BCAX) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a report published on Wednesday,Benzinga reports. The brokerage currently has a $31.00 price target on the stock.

BCAX has been the subject of a number of other research reports. HC Wainwright increased their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective for the company. Finally, RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Performance

NASDAQ BCAX opened at $13.48 on Wednesday. Bicara Therapeutics has a 12 month low of $11.10 and a 12 month high of $28.09. The stock has a 50 day simple moving average of $14.98.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, research analysts expect that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Several large investors have recently added to or reduced their stakes in BCAX. First Turn Management LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $14,324,000. The Manufacturers Life Insurance Company acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $582,000. FMR LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $57,913,000. Walleye Capital LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $809,000. Finally, Vestal Point Capital LP acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at $10,825,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.